Sentry Investment Management LLC Has $72,000 Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Sentry Investment Management LLC decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 32.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 686 shares of the medical equipment provider’s stock after selling 334 shares during the quarter. Sentry Investment Management LLC’s holdings in Zimmer Biomet were worth $72,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in ZBH. International Assets Investment Management LLC increased its position in Zimmer Biomet by 19,988.0% during the 3rd quarter. International Assets Investment Management LLC now owns 107,471 shares of the medical equipment provider’s stock worth $11,601,000 after buying an additional 106,936 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Zimmer Biomet by 15.9% in the third quarter. Assenagon Asset Management S.A. now owns 28,145 shares of the medical equipment provider’s stock valued at $3,038,000 after acquiring an additional 3,859 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Zimmer Biomet by 26.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,511 shares of the medical equipment provider’s stock worth $1,895,000 after acquiring an additional 3,633 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in Zimmer Biomet by 14.3% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 14,672 shares of the medical equipment provider’s stock worth $1,584,000 after purchasing an additional 1,835 shares in the last quarter. Finally, Integrated Advisors Network LLC bought a new stake in Zimmer Biomet in the 3rd quarter valued at about $387,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 0.8 %

Shares of NYSE:ZBH opened at $104.03 on Friday. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $133.90. The company has a market capitalization of $20.71 billion, a PE ratio of 23.38, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The company has a fifty day moving average of $105.78 and a 200-day moving average of $107.40.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the firm posted $2.20 earnings per share. On average, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Analysts Set New Price Targets

Several brokerages have recently commented on ZBH. Barclays lowered their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th. Stifel Nicolaus raised their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Truist Financial restated a “hold” rating and issued a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Finally, Royal Bank of Canada cut their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.